KBC Securities - Autolus Therapeutics ADS (AUTL) Autolus 2Q24 update holds no surprises, obe-cel r/r ALL PDUFA in 4Q24

Report

KBC Securities

Jacob Mekhael

Autolus 2Q24 update holds no surprises, obe-cel r/r ALL PDUFA in 4Q24

Autolus reported 2Q24 results in line with expectations, with 2H24 set to be an eventful period for the company. We look forward to FDA decision on obe-cel (CD19 CAR-T) in r/r adult ALL in 4Q24 (PDUFA 16 November) and believe the odds of approval are solid based on the dataset to date. Beyond oncology, initial data from the phase 1 study of obe-cel in SLE will be one to watch, and if positive, could position obe-cel as a pipeline in a product. We reiterate our $11 TP and BUY rating. Autolus remains one of our life sciences top picks, and we see the recent share price dip as a buying opportunity ahead of an eventful 2H24.

08/08/2024 1 EN

Underlying

Autolus Therapeutics ADS

See profile

US05280R1005 NASDAQ Stock Market United Kingdom

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Autolus FIRST LOOK: 3Q24 update focusses on Aucatzyl's launch in r/r adult ALL

Yesterday before US market opens, Autolus reported 3Q24 results with a cash position of $657.1m (YE23: $239.9m), sufficient to drive Aucatzyl's (obe-cel, CD19 CAR-T) launch in r/r adult ALL, and advance the company's pipeline towards pivotal autoimmune data (KBCSe 2028). The focus of the 3Q24 update was Aucatzyl's upcoming launch, and we expect the large safety differentiation vs. Tecartus to be a key factor for adoption. In parallel, we look forward to initial autoimmune data in 1Q25, which has the potential to expand Aucatzyl's commercial opportunity and bring upside to the stock. We reitera...

November 13, 2024 November 13, 2024 1 EN

KBC Securities

Morning Notes : ABN NA, XIOR BB, IMCD NA, AUTL US, TKWY NA

: ABN NA, XIOR BB, IMCD NA, AUTL US, TKWY NA

November 13, 2024 November 13, 2024 1 EN

GlobeNewsWire

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus from Blackstone Marketing authorizations for obe-cel under review with both the MHRA EMAMatthias Will M.D. appointed as Chief Development Officer, effective September 30, 2024Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bo...

November 12, 2024 November 12, 2024 1 EN

Bekaert Feedback conference call

Below is the feedback from the 3Q conference call. Bekaert lowered its FY guidance to an uEBIT range of 340-350m, which at midpoint is c. 9% below our forecast (378m) and 8% below consensus (373m), reflecting weaker end markets. Importantly and taking into account the solid balance sheet (net debt/EBITDA below 1x) and limited recent M&A activity, Bekaert announced to immediately resume share buybacks and launched a € 200m (>10% of current market cap) SBB program, to be executed over the next 24 months. Despite the reduced FY guidance which will prompt a revision of our forecasts, we welcome th...

22h / 15m 22h / 15m 1 EN

Jacob Mekhael

Jacob Mekhael

Inventiva FIRST LOOK: 3Q24 update holds no surprises, NATiV3 timelines reiterated

Inventiva provided a 3Q24 update which holds no surprises, reporting a cash position of € 13.9m. Following the € 94m in gross proceeds from the tranched equity raise (up to € 348m) announced in October 2024 and € 10m milestone from China partner CTTQ, Inventiva has a cash runway until the end of 2Q25 – this can be further extended with subsequent tranches based on certain conditions being met. With the financing overhang lifted, the focus is on recruitment for the phase 3 (NATiV3) trial of lanifibranor in NASH/MASH, where last screening and randomisation continue to be guided for YE24, and 1H...

November 22, 2024 November 22, 2024 1 EN

Sharad Kumar S.P

Sharad Kumar S.P

Ackermans & van Haaren 3Q FY24: Major Participations Continue To Post Robust Results

The private banking division continued to post robust results with AuM rising 12.1% to a record high of €73.1b while gross inflows stood at €5.1b. These figures do not include AuM upticks from the acquisitions of Box Consultants and Dierickx Leys – these will show up in 4Q FY24 and 1H FY25 respectively. Yesterday, AvH published its updated shareholder arrangement with the Delen family that implied a transfer price of 15x PE + 50.0% of excess equity, implying a value of €4.0b+ (vs. ~€3.0b KBCSe). DEME's sales came in at €1.1b, up 34.8% YoY, driven by strong demand across all contracting segment...

November 22, 2024 November 22, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Autolus 2Q24 update holds no surprises, obe-cel r/r ALL PDUFA in 4Q24

We are a financial services provider for several types of professional clients, each with distinct needs.

Autolus FIRST LOOK: 3Q24 update focusses on Aucatzyl's launch in r/r adult ALL

Morning Notes : ABN NA, XIOR BB, IMCD NA, AUTL US, TKWY NA

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Bekaert Feedback conference call

Inventiva FIRST LOOK: 3Q24 update holds no surprises, NATiV3 timelines reiterated

Ackermans & van Haaren 3Q FY24: Major Participations Continue To Post Robust Results

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe